CGEM Stock Overview
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States.
Notes are coming soon
Cullinan Oncology, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.15|
|52 Week High||US$15.89|
|52 Week Low||US$7.30|
|1 Month Change||10.18%|
|3 Month Change||-18.14%|
|1 Year Change||-13.16%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-62.72%|
Recent News & Updates
|CGEM||US Biotechs||US Market|
Return vs Industry: CGEM underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: CGEM underperformed the US Market which returned -8.5% over the past year.
|CGEM Average Weekly Movement||6.8%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: CGEM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CGEM's weekly volatility (7%) has been stable over the past year.
About the Company
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company’s lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein.
Cullinan Oncology, Inc. Fundamentals Summary
|CGEM fundamental statistics|
Is CGEM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CGEM income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||2.68|
|Net Profit Margin||0.00%|
How did CGEM perform over the long term?See historical performance and comparison